Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 1, 2009, Pages 1-9

  Feki, Anis ^a   Berardi, Philip ^a   Bellingan, Geoff ^b   Major, Attila ^a   Krause, Karl Heinz ^c   Petignat, Patrick ^a   Zehra, Rubab ^d,e   Pervaiz, Shazib ^d,f,g,h   Irminger Finger, Irmgard ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

^h SINGAPORE MIT ALLIANCE   (Singapore)

Author keywords

Animal cancer model; Metastasis; NuTu 19 cells; Ovarian cancer

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

AGE; ASCITES; BLOOD VESSEL OCCLUSION; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER MORTALITY; CANCER PREVENTION; CELL LABELING; CELL LINE; CELL MIGRATION; CELL SPREADING; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; EPITHELIUM CELL; FEMALE; FISCHER 344 RAT; HUMAN; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHATIC DRAINAGE; NONHUMAN; OMENTUM; OVARY CANCER; PERITONEAL CAVITY; PERITONEUM METASTASIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TISSUE PREPARATION; TRANSVAGINAL ECHOGRAPHY;

ANIMALS; ASCITES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RATS; RATS, INBRED F344;

EID: 69249235702     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.12.003     Document Type: Review

References (38)

1. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
2. Bray F., Sankila R., Ferlay J., and Parkin D.M. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38 (2002) 99-166
3. Chhieng D.C., Cangiarella J.F., Zakowski M.F., Goswami S., Cohen J.M., and Yee H.T. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 93 (2001) 330-336
4. Flessner M.F. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 288 (2005) F433-442
5. Carmignani C.P., Sugarbaker T.A., Bromley C.M., and Sugarbaker P.H. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 22 (2003) 465-472
6. Ph S. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology (1995), Kluwer Academic Publisher
7. Salehi F., Dunfield L., Phillips K.P., Krewski D., and Vanderhyden B.C. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 11 (2008) 301-321
8. Auersperg N., Wong A.S., Choi K.C., Kang S.K., and Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22 (2001) 255-288
9. Tan D.S., Agarwal R., and Kaye S.B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7 (2006) 925-934
10. Gasparini G., Longo R., Toi M., and Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2 (2005) 562-577
11. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25 (2007) 5165-5171
12. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
13. Kenny H.A., Kaur S., Coussens L.M., and Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 118 (2008) 1367-1379
14. Kajiyama H., Shibata K., Terauchi M., Ino K., Nawa A., and Kikkawa F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122 (2008) 91-99
15. Bansal S., Kaur K., and Bansal A.K. Diagnosing ascitic etiology on a biochemical basis. Hepatogastroenterology 45 (1998) 1673-1677
16. Runyon B.A., Hoefs J.C., and Morgan T.R. Ascitic fluid analysis in malignancy-related ascites. Hepatology 8 (1988) 1104-1109
17. Kraft A., Weindel K., Ochs A., et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85 (1999) 178-187
18. Xu L., Yoneda J., Herrera C., Wood J., Killion J.J., and Fidler I.J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16 (2000) 445-454
19. Mesiano S., Ferrara N., and Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153 (1998) 1249-1256
20. Hu L., Hofmann J., Zaloudek C., Ferrara N., Hamilton T., and Jaffe R.B. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161 (2002) 1917-1924
21. Neesham D. Ovarian cancer screening. Aust Fam Physician 36 (2007) 126-128
22. Bast Jr. R.C., Brewer M., Zou C., et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results. Cancer Res 174 (2007) 91-100
23. Moore R.G., Brown A.K., Miller M.C., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108 (2008) 402-408
24. Ayhan A., Gultekin M., Dursun P., et al. Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance?. Gynecol Oncol 108 (2008) 428-432
25. Tetsche M.S., Dethlefsen C., Pedersen L., Sorensen H.T., and Norgaard M. The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer 8 (2008) 31
26. Dizon D.S., Restivo A., Lomme M., et al. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?. Am J Clin Oncol 31 (2008) 39-42
27. Pisani P., Bray F., and Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97 (2002) 72-81
28. Fu X., and Hoffman R.M. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 13 (1993) 283-286
29. Sekiya S., Endoh N., Kikuchi Y., et al. In vivo and in vitro studies of experimental ovarian adenocarcinoma in rats. Cancer Res 39 (1979) 1108-1112
30. Pretorius R.G., Eisenkop S., Berek J.S., et al. Utilization of a murine model to optimize volume and dwell time of intraperitoneal cisplatin. Gynecol Oncol 34 (1989) 66-69
31. Ishiwata K., Tomura M., Ido T., et al. 6-[18F]fluoro-L-fucose: a possible tracer for assessing glycoconjugate synthesis in tumors with positron emission tomography. J Nucl Med 31 (1990) 1997-2003
32. Rose G.S., Tocco L.M., Granger G.A., et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol 175 (1996) 593-599
33. Bellingan G.J., Caldwell H., Howie S.E., Dransfield I., and Haslett C. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol 157 (1996) 2577-2585
34. Beelen R.H., Fluitsma D.M., and Hoefsmit E.C. The cellular composition of omentum milky spots and the ultrastructure of milky spot macrophages and reticulum cells. J Reticuloendothel Soc 28 (1980) 585-599
35. Testa J.R., Getts L.A., Salazar H., et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 54 (1994) 2778-2784
36. Dull T., Zufferey R., Kelly M., et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 72 (1998) 8463-8471
37. Zufferey R., Nagy D., Mandel R.J., Naldini L., and Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15 (1997) 871-875
38. Workman P., Balkwill T.P., Balmain F., et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia. Br J Cancer (second edition) 77 (1998) 1-10